UNH Stock Analysis: UnitedHealth | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 336.787m USD | 12M Return: 9.6% | US91324P1021 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.82B
EPS Trend: -71.7%
Qual. Beats: 2
Rev. Trend: 99.3%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
UnitedHealth Group is a diversified U.S. health care company organized into two main platforms: UnitedHealthcare, its insurance arm offering employer-sponsored, individual, Medicare, and Medicaid plans, and Optum, which provides health services, pharmacy benefits management, and technology/consulting to providers, payers, and other organizations. The business model combines risk-bearing insurance products with care delivery and pharmacy operations, creating vertical integration across the health care value chain.
The company serves a broad customer base spanning national and mid-sized employers, small businesses, public-sector programs (including Medicaid, CHIP, and Dual SNPs), and individual consumers. Founded in 1974 and headquartered in Eden Prairie, Minnesota, UNH operates in the Managed Health Care sub-industry and is listed on the NYSE.
- Optum Health and Optum Rx drive earnings growth and margin expansion
- Medicare Advantage star ratings and reimbursement rate updates impact UnitedHealthcare margins
- Change Healthcare cyberattack fallout pressures earnings and drives elevated remediation costs
| Net Income: 14.1b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.56 > 1.0 |
| NWC/Revenue: -5.55% < 20% (prev -4.04%; Δ -1.51% < -1%) |
| CFO/TA 0.09 > 3% & CFO 27.0b > Net Income 14.1b |
| Net Debt (41.9b) to EBITDA (25.8b): 1.62 < 3 |
| Current Ratio: 0.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (906.0m) vs 12m ago -0.44% < -2% |
| Gross Margin: 22.49% > 18% (prev 20.84%; Δ 1.64% > 0.5%) |
| Asset Turnover: 145.6% > 50% (prev 137.0%; Δ 8.58% > 0%) |
| Interest Coverage Ratio: 5.52 > 6 (EBIT TTM 21.5b / Interest Expense TTM 3.89b) |
| A: -0.08 (Total Current Assets 86.9b - Total Current Liabilities 112b) / Total Assets 310b |
| B: 0.33 (Retained Earnings 101b / Total Assets 310b) |
| C: 0.07 (EBIT TTM 21.5b / Avg Total Assets 309b) |
| D: 0.48 (Book Value of Equity 98.4b / Total Liabilities 204b) |
| Altman-Z'' = 1.51 = BB |
| DSRI: 0.82 (Receivables 46.3b/52.7b, Revenue 450b/423b) |
| GMI: 0.93 (GM 20.84% / 22.49%) |
| AQI: 1.04 (AQ_t 0.68 / AQ_t-1 0.66) |
| SGI: 1.06 (Revenue 450b / 423b) |
| TATA: -0.04 (NI 14.1b - CFO 27.0b) / TA 310b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of September 24, 2026, the stock is trading at USD 371.29 with a total of 3,861,359 shares traded. Over the past week, the price has changed by -1.06%, over one month by -6.32%, over three months by -8.72% and over the past year by +9.63%.
Current recommended Stop Loss: 360.40 (which is 2.9% or 1.2 ATR below the current price).
UnitedHealth has received a consensus analysts rating of 4.15. Therefore, it is recommended to buy UNH.
- StrongBuy: 14
- Buy: 6
- Hold: 5
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 481.7 | 29.7% |
P/E Trailing = 24.0983
P/E Forward = 16.7224
P/S = 0.7475
P/B = 3.4215
P/EG = 1.0195
Revenue TTM = 450b USD
EBIT TTM = 21.5b USD
EBITDA TTM = 25.8b USD
Long Term Debt = 69.5b USD (from longTermDebt, last quarter)
Short Term Debt = 3.83b USD (from shortTermDebt, last quarter)
Debt = 73.3b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 41.9b USD (calculated: Debt 73.3b - CCE 31.5b)
Enterprise Value = 379b USD (337b + Debt 73.3b - CCE 31.5b)
Interest Coverage Ratio = 5.52 (Ebit TTM 21.5b / Interest Expense TTM 3.89b)
EV/FCF = 16.03x (Enterprise Value 379b / FCF TTM 23.6b)
FCF Yield = 6.24% (FCF TTM 23.6b / Enterprise Value 379b)
FCF Margin = 5.25% (FCF TTM 23.6b / Revenue TTM 450b)
Net Margin = 3.14% (Net Income TTM 14.1b / Revenue TTM 450b)
Gross Margin = 22.49% ((Revenue TTM 450b - Cost of Revenue TTM 349b) / Revenue TTM)
Gross Margin QoQ = 32.74% (prev 22.74%)
Tobins Q-Ratio = 1.22 (Enterprise Value 379b / Total Assets 310b)
Interest Expense / Debt = 5.31% (Interest Expense 3.89b / Debt 73.3b)
Taxrate = 14.50% (2.53b / 17.4b)
NOPAT = 18.4b (EBIT 21.5b * (1 - 14.50%))
Current Ratio = 0.78 (Total Current Assets 86.9b / Total Current Liabilities 112b)
Debt / Equity = 0.74 (Debt 73.3b / totalStockholderEquity, last quarter 98.4b)
Debt / EBITDA = 1.62 (Net Debt 41.9b / EBITDA 25.8b)
Debt / FCF = 1.77 (Net Debt 41.9b / FCF TTM 23.6b)
Total Stockholder Equity = 96.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.57% (Net Income 14.1b / Total Assets 310b)
RoE = 14.63% (Net Income TTM 14.1b / Total Stockholder Equity 96.6b)
RoCE = 12.93% (EBIT 21.5b / Capital Employed (Equity 96.6b + L.T.Debt 69.5b))
RoIC = 10.25% (NOPAT 18.4b / Invested Capital 179b)
WACC = 5.43% (E(337b)/V(410b) * Re(5.62%) + D(73.3b)/V(410b) * Rd(5.31%) * (1-Tc(0.14)))
Discount Rate = 5.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -87.51 | Cagr: -0.78%
[DCF] Terminal Value 74.51% ; FCFF base≈24.3b ; Y1≈23.0b ; Y5≈21.8b
[DCF] Fair Price = 335.9 (EV 343b - Net Debt 41.9b = Equity 302b / Shares 897.6m; r=8.35% [WACC [floored]]; 5y FCF grow -6.55% → 2.50% )
EPS Correlation: -71.65 | EPS CAGR: -14.66% | SUE: 4.0 | # QB: 2
Revenue Correlation: 99.25 | Revenue CAGR: 9.02% | SUE: 0.93 | # QB: 2
EPS current Quarter (2026-09-30): EPS=4.15 | Chg30d=+0.75% | Revisions=+38% | Analysts=23
EPS current Year (2026-12-31): EPS=19.87 | Chg30d=+0.28% | Revisions=+57% | GrowthEPS=+21.5% | GrowthRev=-0.1%
EPS next Year (2027-12-31): EPS=22.61 | Chg30d=+0.78% | Revisions=+44% | GrowthEPS=+13.8% | GrowthRev=+2.8%
[Analyst] Revisions Ratio: +61% (up=13, down=2)